Stanley Abel
Director/Board Member chez ADYNXX, INC.
Profil
Stanley E.
Abel was the founder of Cerexa, Inc. (founded in 2005) where he served as the Chief Financial Officer in 2007.
He is currently the President, Chief Executive Officer & Director at ProJenX, Inc., Chairman at SiteOne Therapeutics, Inc. (since 2014), Chairman & President at The Montana Bioscience Alliance, and an Independent Director at Adynxx, Inc. (since 2008).
Mr. Abel previously held the position of Chief Executive Officer at Corthera, Inc. from 2007 to 2010.
He also served as Chairman of the Biotechnology Innovation Organization and Director at Adynxx, Inc. (Old).
Additionally, he worked as a Principal at Eli Lilly & Co. and Chief Financial Officer at Peninsula Pharmaceuticals, Inc. from 2003 to 2005.
Mr. Abel's education includes an undergraduate degree from Indiana University and an MBA from The University of Chicago.
Postes actifs de Stanley Abel
Sociétés | Poste | Début |
---|---|---|
ADYNXX, INC. | Director/Board Member | 01/01/2008 |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | Chairman | 23/03/2021 |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | Chairman | - |
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Chief Executive Officer | 01/04/2022 |
Anciens postes connus de Stanley Abel
Sociétés | Poste | Fin |
---|---|---|
Corthera, Inc.
Corthera, Inc. Pharmaceuticals: MajorHealth Technology Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA. | Chief Executive Officer | 01/02/2010 |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Founder | 01/01/2007 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Director of Finance/CFO | 01/05/2005 |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Chairman | - |
Adynxx, Inc. (Old)
Adynxx, Inc. (Old) Pharmaceuticals: MajorHealth Technology Adynxx, Inc. develops clinical-stage pharmaceutical addressing pain at its molecular roots. Its technology platform provides treating the development of pain following surgery or trauma and established chronic pain syndrome. The company was founded by Julien Mamet in October 2007 and is headquartered in San Francisco, CA. | Director/Board Member | - |
Formation de Stanley Abel
Indiana University | Undergraduate Degree |
The University of Chicago | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
ADYNXX, INC. | Health Technology |
Entreprise privées | 9 |
---|---|
Corthera, Inc.
Corthera, Inc. Pharmaceuticals: MajorHealth Technology Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA. | Health Technology |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Commercial Services |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Adynxx, Inc. (Old)
Adynxx, Inc. (Old) Pharmaceuticals: MajorHealth Technology Adynxx, Inc. develops clinical-stage pharmaceutical addressing pain at its molecular roots. Its technology platform provides treating the development of pain following surgery or trauma and established chronic pain syndrome. The company was founded by Julien Mamet in October 2007 and is headquartered in San Francisco, CA. | Health Technology |
Sonexa Therapeutics, Inc.
Sonexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sonexa Therapeutics, Inc. developed drug treatments for Alzheimer's disease (AD) and related disorders. Its lead compound, ST101 had demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. The company was founded in January 2008 and was headquartered in San Diego, CA. | Health Technology |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | Health Technology |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | Commercial Services |
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Commercial Services |